ABBV

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

Retrieved on: 
Monday, April 1, 2024
AbbVie, AstraZeneca, THL, ABBV, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, AdTheorent will be acquired by Cadent, LLC (“Cadent”).
  • The Company’s common stockholders will receive cash consideration of $3.21 per share.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

Retrieved on: 
Monday, April 1, 2024
Research, Growth, JV, Amazon, Health, Partnership, International, Webcast, ABBV, Foot, Acquisition, Cellulite, OTC, Marketing, Advertising, Stada Arzneimittel, Video game

Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.

Key Points: 
  • Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.
  • Our nearly 100% year-over-year revenue growth in 2023 was primarily driven by our branded products and contract manufacturing.
  • The increase in revenue was primarily due to sales growth in contract manufacturing of 166% and an increase in branded product revenue by approximately $427,000, or 52.4%, to $1.24 million.
  • For the fourth quarter of 2023, branded products revenue was $392,000, an increase of 104.2% year-over-year and 10.1% sequentially.

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Antioxidant, MSRP, Nicotinamide, Physician, Patient, ABBV, Senior, Trial of the century, Acne, Skin, Aloe, Yale University, Salicylic acid, Cosmetics

The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.

Key Points: 
  • The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.
  • "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne."
  • In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out.
  • "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

Retrieved on: 
Monday, March 25, 2024
AbbVie, AstraZeneca, THL, ABBV, Sale, Base, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Agiliti will be acquired by Thomas H. Lee Partners, L.P. (“THL”).
  • Under the terms of the agreement, Landos Biopharma will be acquired by AbbVie Inc. (“AbbVie”) (NYSE - ABBV).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Retrieved on: 
Monday, March 25, 2024
AbbVie, Ulcerative colitis, Patient, Inflammation, ABBV, Acquisition, IBD, MOA, Therapy, NLRX1, Calendar, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
  • Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
  • “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease.
  • The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

Retrieved on: 
Wednesday, March 27, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, ABBV, Sale, AbbVie

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

AbbVie to Host First-Quarter 2024 Earnings Conference Call

Retrieved on: 
Thursday, April 4, 2024
AbbVie, ABBV

4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.

Key Points: 
  • 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.
  • AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.
  • It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com .
  • An archived edition of the session will be available later that day.

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Retrieved on: 
Friday, March 22, 2024
AbbVie, Ovarian cancer, Survival, ImmunoGen, Progression-free survival, Patient, Neoplasm, ABBV, Malignancy, University, Mirvetuximab soravtansine, PROC, Cancer, PFS, ADC, Food, FDA, Medicine, Pharmaceutical industry

NORTH CHICAGO, Ill., March 22, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They may become resistant to this treatment and require another therapy, such as ELAHERE.  

Key Points: 
  • Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy.
  • They may become resistant to this treatment and require another therapy, such as ELAHERE.
  • "The full FDA approval of ELAHERE for eligible patients with ovarian cancer represents the culmination of years of work by the ImmunoGen team.
  • "As the first treatment to show a statistically significant overall survival benefit in patients with platinum-resistant ovarian cancer, ELAHERE provides an effective new option for patients with folate receptor alpha positive tumors.

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

Retrieved on: 
Tuesday, March 5, 2024
MRK, Hospital, News, FOLFIRINOX, Growth, AbbVie, PR, Neutrophil, Poster, Diagnosis, Pancreatic cancer, HBV, Incidence, Cancer, TME, Hepatology, Interleukin, Therapy, Prostate cancer, Liver, Immune system, Partnership, Merck & Co., AIO, PSMA, Inflammation, Safety, TILS, GPCR, Tumor microenvironment, Research, Medication, PALM, ABBV, Merck, Macrophage, Blood, FDA, TSX, Food, Ageing, Pembrolizumab, Pancreatic Cancer Action Network, Government, Prevalence, Ocean Biomedical, LAVA, PDAC, Patient, MHRA, Disease, ONC, PEI, Pharmaceutical industry

Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.

Key Points: 
  • Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.
  • The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers.
  • A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029.
  • Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment.